Rituximab for refractory IgA vasculitis nephritis with podocyte injury in a patient with ankylosing spondylitis on secukinumab therapy: a case report
Year: 2026
Type: article
Study design: Case Report
Abstract: Background IgA vasculitis nephritis (IgAVN) with podocyte injury is a treatment-refractory subtype of IgA vasculitis that often responds poorly to glucocorticoids and is accompanied by persistent proteinuria. New-onset IgAVN during interleukin-17A (IL-17A) inhibitor therapy in patients with ankylosing spondylitis (AS) is extremely rare. Case presentation A 24-year-old, HLA-B27–positive man with axial-predominant AS on long-term secukinumab developed palpable purpura after an influenza virus infection, followed by hematuria and proteinuria. Renal biopsy revealed proliferative necrotizing IgAVN (ISKDC grade III) with diffuse podocyte foot-process effacement. Prednisone 30 mg/day for 6 days did not improve proteinuria (24-h urinary protein increased from 1.28 g to 1.44 g) and axial AS symptoms relapsed. Glucocorticoids were replaced with rituximab (RTX) 500 mg intravenously every 7–10 days for 4 infusions, with concomitant discontinuation of secukinumab. Results Four weeks after the first infusion, peripheral blood CD19+ B cells were completely depleted and 24-h urinary protein decreased to 0.83 g; at 6 months it was 0.06 g and remained negative, with serum albumin normalized. AS remained stable after IL-17A inhibitor withdrawal (BASDAI score of 0). One pulmonary infection occurred during RTX treatment and resolved with anti-infective therapy. Conclusion RTX may be an effective option for IgAVN with podocyte injury and inadequate glucocorticoid response in patients with AS, and may help maintain AS stability after IL-17A inhibitor discontinuation.
Source: Frontiers in Medicine
Institution: First Affiliated Hospital of Wannan Medical College
Language: English
Subfield: Nephrology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,801
OpenAlex ID: W7236300318
